Hangzhou Synrx Therapeutics Biomedical Technology Co. Ltd. recently presented the development and characterization of a novel PARG inhibitor, SYN-608, for the potential treatment of tumors with/without homologous recombination deficiency (HRD).
Tumor cell survival is dependent on phosphate homeostasis, which requires high amounts of energy. Researchers have demonstrated that the silencing of xenotropic and polytropic retrovirus receptor 1 (XPR1) led to reduced tumor growth in an ovarian cancer cell line xenograft, and similar vulnerability was found in lung cancer.
Hepatocellular carcinoma (HCC) is the most common type of liver cancer, with a 5-year survival rate of 18%. Glypican-3 (GPC3) is a protein with high expression in HCC but not in healthy tissue, making it an interesting target for therapy.
Researchers from Bright Biologics LLC presented the discovery and preclinical characterization of a novel bispecific anti-Her2/anti-Trop2 antibody-drug conjugate (ADC), BB-201.
Researchers from Naya Biosciences Inc. and collaborators presented preclinical data on NY-303, a natural killer (NK) cell engager bispecific antibody targeting both GPC3 and NKp46. NKp46 is a cell surface receptor involved in NK cell activation and the elimination of target cancer cells.
Researchers from the U.K. have analyzed whole-genome sequencing data from 7,276 cases and 236,741 controls in the UK Biobank to perform gene-level and a variant-level exome-wide association study analysis to identify variants related to retinal detachment.
Telix Pharmaceuticals Ltd. is expanding its theranostic pipeline with new assets targeting fibroblast activation protein (FAP). The company has entered into asset purchase and exclusive worldwide in-license agreements for a suite of clinically validated FAP-targeting therapeutic and precision medicine (diagnostic) radiopharmaceutical candidates developed at Johannes Gutenberg-Universität Mainz.
Siren Biotechnology Inc. has unveiled its lead asset, SRN-101, for the treatment of high-grade gliomas. The FDA has granted orphan drug and rare pediatric disease designations to SRN-101 for high-grade gliomas and pediatric-type diffuse high-grade gliomas, respectively.
The bromodomain and extra terminal domain (BET) family of proteins, including BRD4, regulates the transcription of multiple proinflammatory and immunoregulatory genes. BRD4 is involved in immune-related disorders such as rheumatoid arthritis (RA).
RSS
